TLDR
- QURE drops 34% after FDA calls for Phase III trial
- FDA rejects AMT-130 data; QURE shares sink
- uniQure slides as regulators demand new study
- Huntington’s therapy setback hits QURE stock
- FDA decision triggers sharp selloff in QURE
QURE stock sinks as the FDA calls for a randomized Phase III trial for its Huntington’s therapy. The shares fell 34.74% to $10.20, losing $5.43 during the session. The sharp decline followed regulatory feedback on AMT-130, and it pressured uniQure N.V. stock early.
FDA rejects Phase I/II data as primary evidence
The U.S. Food and Drug Administration reviewed data from Phase I/II studies of AMT-130 for Huntington’s disease. The agency stated that the studies cannot serve as primary evidence of effectiveness. As a result, the FDA urged the company to conduct a prospective, randomized, double-blind, sham surgery-controlled trial.
The agency issued its position in final minutes from a Type A meeting held on January 30, 2026. The meeting focused on whether existing data could support a future marketing application. However, regulators concluded that comparisons to external controls were not sufficient for approval.
This feedback directly affected uniQure N.V. stock, which reacted with heavy selling pressure. The market reassessed development timelines and regulatory risks. Consequently, uniQure N.V. stock recorded one of its steepest single-day declines this year.
Company outlines next regulatory steps
uniQure confirmed that it will continue discussions with the FDA regarding Phase III development plans. The company plans to request a Type B meeting in the second quarter of 2026. That meeting will address potential study design options for a late-stage trial.
Management acknowledged that regulators did not support a submission based solely on Phase I/II data. The company maintains that the totality and durability of its results justify continued dialogue. Therefore, uniQure aims to establish a clear and efficient regulatory pathway.
The regulatory update increased uncertainty around timelines and costs. A randomized, sham-controlled study will likely extend development and require additional capital. As a result, uniQure N.V. stock faced renewed volatility following the announcement.
AMT-130 program and broader context
AMT-130 is an investigational gene therapy designed to treat Huntington’s disease, a rare and fatal genetic disorder. The therapy aims to slow disease progression by targeting the underlying genetic cause. Huntington’s disease currently lacks curative treatments, and patients face progressive neurological decline.
uniQure specializes in gene therapy and focuses on severe diseases with high unmet needs. The company has advanced several programs using its proprietary platform technology. However, regulatory pathways for novel gene therapies remain complex and demand robust clinical evidence.
The latest FDA feedback reshapes the development strategy for AMT-130 and influences near-term expectations. uniQure N.V. stock remains sensitive to regulatory milestones and clinical updates. Going forward, uniQure N.V. stock will reflect progress toward a randomized Phase III trial and further FDA engagement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
